ProSomnus EVO stabilises the jaw during sleep and improves airflow through the pharyngeal space of the patient. Credit: Andisheh A on Unsplash.

ProSomnus has enrolled the first participant in its Severe Obstructive Sleep Apnea (SOS) study of ProSomnus EVO Sleep and Snore device.

The FDA-reviewed, single-arm, multi-centre, prospective study has been designed to assess the efficacy and safety of precision oral appliance therapy (OAT) with the Sleep and Snore device in severe obstructive sleep apnea (OSA) patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The study’s two primary endpoints are safety and efficacy.

In the study, researchers will evaluate the efficacy of ProSomnus EVO by measuring the apnea-hypopnea index (AHI) and oxygen desaturation index (ODI) of the participants six months after initiating precision OAT.

ProSomnus EVO’s safety will be assessed by reviewing all the reported adverse events, safety evaluations, and dental checks.

ProSomnus chief scientist John Remmers said: “Many patients with severe OSA are in dire need of treatment, and previous research suggests that ProSomnus’ precision OAT devices could successfully treat most patients’ OSA.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Further establishing the efficacy and safety of precision OAT in this study could lead to the wider adoption of a much-needed alternative to CPAP, which many patients cannot adhere to because of the discomfort it can cause.”

The company stated that ProSomnus EVO is an alternative to legacy dental products as well as CPAP machines.

It can be completely customised based on the patient’s anatomy and treatment plan.

The device precisely repositions and stabilises the jaw during sleep that helps in improving the airflow through a pharyngeal space of the patient.

It comprises maxillary and mandibular aligners which are precision-manufactured with twin-mated posts.

The company is planning to use the data from the SOS study to seek an extended indication for use with the US Food and Drug Administration (FDA).

If the trial is successful, ProSomnus EVO will become the first intraoral medical device approved to treat severe OSA patients.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact